Simple, Visual, Point-of-Care SARS-CoV-2 Detection Incorporating Recombinase Polymerase Amplification and Target DNA–Protein Crosslinking Enhanced Chemiluminescence

Hui Chen,Zhiyuan Zhuang,Naihan Xu,Ying Feng,Kaixin Fang,Chunyan Tan,Ying Tan
DOI: https://doi.org/10.3390/bios14030135
2024-03-07
Biosensors
Abstract:The ongoing COVID-19 pandemic, driven by persistent SARS-CoV-2 transmission, threatens human health worldwide, underscoring the urgent need for an efficient, low-cost, rapid SARS-CoV-2 detection method. Herein, we developed a point-of-care SARS-CoV-2 detection method incorporating recombinase polymerase amplification (RPA) and DNA–protein crosslinking chemiluminescence (DPCL) (RPADPCL). RPADPCL involves the crosslinking of biotinylated double-stranded RPA DNA products with horseradish peroxidase (HRP)-labeled streptavidin (SA-HRP). Modified products are captured using SA-labeled magnetic beads, and then analyzed using a chemiluminescence detector and smartphone after the addition of a chemiluminescent substrate. Under optimal conditions, the RPADPCL limit of detection (LOD) was observed to be 6 copies (within the linear detection range of 1–300 copies) for a plasmid containing the SARS-CoV-2 N gene and 15 copies (within the linear range of 10–500 copies) for in vitro transcribed (IVT) SARS-CoV-2 RNA. The proposed method is convenient, specific, visually intuitive, easy to use, and does not require external excitation. The effective RPADPCL detection of SARS-CoV-2 in complex matrix systems was verified by testing simulated clinical samples containing 10% human saliva or a virus transfer medium (VTM) spiked with a plasmid containing a SARS-CoV-2 N gene sequence or SARS-CoV-2 IVT RNA. Consequently, this method has great potential for detecting targets in clinical samples.
chemistry, analytical,nanoscience & nanotechnology,instruments & instrumentation
What problem does this paper attempt to address?
The problem this paper attempts to address is the development of an efficient, low-cost, and rapid method for detecting SARS-CoV-2. Specifically, the research team proposes a new method that combines Recombinase Polymerase Amplification (RPA) and DNA-Protein Crosslinking Enhanced Chemiluminescence (DPCL), abbreviated as RPADPCL. This method aims to achieve rapid, simple, and highly sensitive on-site detection of the SARS-CoV-2 virus. Through this method, the researchers hope to address the complexity, high cost, and need for specialized equipment and personnel associated with traditional RT-qPCR methods. Additionally, compared to immunological detection based on Lateral Flow Assay (LFA), this method offers higher sensitivity and does not require an external excitation light source for chemiluminescence detection. Experimental results show that the RPADPCL method has detection limits of 6 copies and 15 copies for plasmids containing the SARS-CoV-2 N gene and in vitro transcribed RNA, respectively, under optimal conditions, demonstrating good detection performance. Furthermore, this method has been validated in complex sample systems, including simulated clinical samples containing human saliva or viral transport medium. Therefore, the RPADPCL method has great potential for target detection in clinical samples.